Gymnema Gymnema sylvestre (Retz.) R.Br. ex Sm.
Also called: Gymnema sylvestre, Marsdenia sylvestris (synonym)
Gymnema is a perennial climbing vine whose leaves are used in traditional medicine. Leaf extracts are promoted in the United States for blood sugar control and weight loss and are sold as powders or capsules, alone or in combinations.
- Category
- Botanical
- Part used
- Leaf
- Strongest evidence
- B Some positive trials
- Native range
- Native to the tropical and subtropical Old World (POWO: "Tropical & Subtropical Old World")
- Reviewed
- 2026-10-29
Class 2 Moderately studied in people. This entry cites 4 RCTs of Gymnema sylvestre alone (sources [6]–[9]), versus placebo or berberine, in 24 to 58 adults. A 2023 meta-analysis (source [2]) pooled 6 RCTs, but whether each tested gymnema alone could not be confirmed. [6]
Fact-checked 2026-10-29 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
BBlood sugar and weight3 topics
BHeart and blood vessels1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Blood sugar in adults (randomized trials) | B | A 2023 meta-analysis of six randomized trials found lower fasting blood sugar than control; the authors cite notable heterogeneity, low study quality and little diversity among participants. [2] |
| Glycemic control in type 2 diabetes | C | A 2021 meta-analysis (10 studies, 419 participants) reported reductions in fasting and post-meal glucose and HbA1c, but compared post-treatment values with baseline rather than with a control group; heterogeneity was high. [3] |
| Blood lipids and blood pressure | B | The 2023 Zamani meta-analysis of six randomized trials reported lower triglycerides, total and LDL cholesterol and diastolic blood pressure; the authors cite notable heterogeneity and low study quality. [2] |
| Overall effectiveness in diabetes | C | LiverTox states that several human trials showed mild decreases in fasting glucose, but overall effectiveness in diabetes has not been shown. [1] |
Main constituents: Gymnemic acids (triterpene saponins), the most distinctive of more than 50 components; also flavones, anthraquinones, alkaloids, resins and tannins [1]; Gymnemic acids bind to and inhibit human sweet-taste receptors in vitro, and human and animal studies show suppressed taste response to sweet substances [1]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- Trials summarized by LiverTox used 400 mg daily (18 to 20 months), 500 mg twice daily (60 days) and 300 mg twice daily (12 weeks). [1]
No official upper intake level has been set.
Safety and side effects
- Liver (NIH LiverTox)Score DABCDEA: well known causeE: unlikely cause
LiverTox likelihood score D: possible rare cause of clinically apparent liver injury.
Details and sources - Pregnancy and breastfeedingNothing found
No published information found in the sources checked.
Details and sources - Interactions with medicinesNothing found
No published information found in the sources checked.
Details and sources - Cancer evaluations (IARC, NTP)None found
No IARC or NTP evaluation was found in the lists checked.
Details and sources - FDA new dietary ingredient notificationsNone on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
- Liver: LiverTox likelihood score D (possible rare cause of clinically apparent liver injury); there have been rare, isolated case reports, with weak attribution in most. [1]
- Side effects of conventional doses are uncommon but may include nausea, abdominal discomfort, diarrhea, headaches and rash. Long-term safety has not been well documented in humans. [1]
Identity, quality and standardization
- There is little standardization of purity and concentration of extracts in gymnema products. [1]
Regulatory status
- US: FDA states that under DSHEA it does not have the authority to approve dietary supplements before they are marketed; firms are responsible for ensuring their products are not adulterated or misbranded. [5]
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Gymnemic acids Triterpene saponins [P1]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming gymnema (Gymnema sylvestre) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P2]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- No IARC or NTP carcinogenicity evaluation of gymnema (Gymnema sylvestre) was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-29). [P3]
Liver (NIH LiverTox)
- LiverTox likelihood score D: possible rare cause of clinically apparent liver injury. Small, short trials showed no changes in ALT, AST, GGT or bilirubin; effects of long-term use and higher doses have not been assessed in humans (chapter updated 2024-10-28). [P1]
Interactions with medicines
- No published information found in the sources checked.
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity test or examination of the dietary ingredient — 21 CFR 111.75(a)(1)(i) requires at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, unless FDA grants an exemption petition under 111.75(a)(1)(ii). [P4]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- No published information found in the sources checked.
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- No published information found in the sources checked.
Sources for this profile
- NIH LiverTox (NIDDK). Gymnema (Last Update: 2024-10-28), 2024-10-28. ncbi.nlm.nih.gov
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications (list last updated 2026-07-23), 2026-07-23. monographs.iarc.who.int
- eCFR. 21 CFR 111.75 (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
Sources
- NIH LiverTox (NIDDK). Gymnema (Last Update: 2024-10-28), 2024-10-28. ncbi.nlm.nih.gov
- Zamani M, et al. The effects of Gymnema sylvestre supplementation on lipid profile, glycemic control, blood pressure, and anthropometric indices in adults: a systematic review and meta-analysis. Phytother Res 2023;37(3):949-964 (PMID 36580574), 2023-03. pubmed.ncbi.nlm.nih.gov
- Devangan S, et al. The effect of Gymnema sylvestre supplementation on glycemic control in type 2 diabetes patients: a systematic review and meta-analysis. Phytother Res 2021;35(12):6802-6812 (PMID 34467577), 2021-12. pubmed.ncbi.nlm.nih.gov
- Plants of the World Online (POWO), Royal Botanic Gardens, Kew. Gymnema sylvestre (Retz.) R.Br. ex Sm. (accessed 2026-10-29). powo.science.kew.org
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
- Zuñiga LY, et al. Effect of Gymnema sylvestre administration on metabolic syndrome, insulin sensitivity, and insulin secretion. J Med Food 2017;20(8):750-754 (PMID 28459647), 2017-08. pubmed.ncbi.nlm.nih.gov
- Gaytán Martínez LA, et al. Effect of Gymnema sylvestre administration on glycemic control, insulin secretion, and insulin sensitivity in patients with impaired glucose tolerance. J Med Food 2021;24(1):28-32 (PMID 32460589), 2021-01. pubmed.ncbi.nlm.nih.gov
- Turner S, et al. The effect of a 14-day Gymnema sylvestre intervention to reduce sugar cravings in adults. Nutrients 2022;14(24):5287 (PMID 36558446), 2022-12-12. pubmed.ncbi.nlm.nih.gov
- Bandala C, et al. Comparative effects of Gymnema sylvestre and berberine on adipokines, body composition, and metabolic parameters in obese patients: a randomized study. Nutrients 2024;16(14):2284 (PMID 39064727), 2024-07-16. pubmed.ncbi.nlm.nih.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.